Codis, a global contract development and manufacturing organisation (CDMO) specialising in spray drying, amorphous solid dispersions and advanced particle engineering solutions, has entered an agreement with Catalent to acquire its facility in Nottingham, UK.
The acquisition, expected to close in Q3 of this year subject to customary closing conditions, will add oral solid dose (OSD) development and small-scale manufacturing capabilities and create Europe’s leading single partner path for integrated spray dry solutions, from development through clinical supply and commercial intermediates, to final oral dose forms.
The Nottingham site brings a highly experienced team and deep scientific expertise in formulation development and clinical supply, successfully delivering development-scale spray drying and OSD solutions for over two decades. Codis is excited to welcome the Nottingham team into the organisation.
This acquisition will strategically complement Codis’ large scale commercial spray drying facility in Haverhill, UK, which is now undergoing significant expansion with a new GEA Pharma-SD type PSD-4 commercial spray dryer scheduled to be validated in 2027. It will also augment Codis’ current portfolio of bioavailability enhancement solutions with integrated development, analytical and clinical and small-scale commercial manufacturing co-located at the site.
